## Cytokine Storm

<table>
<thead>
<tr>
<th>Recommendation #41</th>
<th>Strength &amp; Quality of Evidence</th>
</tr>
</thead>
</table>
| In mechanically ventilated adults with COVID-19 and respiratory failure (without ARDS), we suggest against the routine use of systemic corticosteroids. | • Weak  
• Low-Quality of Evidence |

<table>
<thead>
<tr>
<th>Recommendation #42</th>
<th>Strength &amp; Quality of Evidence</th>
</tr>
</thead>
</table>
| In mechanically ventilated adults with COVID-19 and ARDS, we suggest using systemic corticosteroids, over not using corticosteroids. | • Weak  
• Low-Quality of Evidence |

<table>
<thead>
<tr>
<th>Recommendation #43</th>
<th>Strength &amp; Quality of Evidence</th>
</tr>
</thead>
</table>
| In mechanically ventilated patients with COVID-19 and respiratory failure, we suggest using empiric antimicrobials/anti-bacterial agents, over no antimicrobials. | • Weak  
• Low-Quality of Evidence |

<table>
<thead>
<tr>
<th>Recommendation #44</th>
<th>Strength &amp; Quality of Evidence</th>
</tr>
</thead>
</table>
| For critically ill adults with COVID-19 who develop fever, we suggest using acetaminophen/paracetamol for temperature control, over no treatment. | • Weak  
• Low-Quality of Evidence |
**Recommendation #45**

In critically ill adults with COVID-19, we **suggest against** the routine use of standard intravenous immunoglobulins (IVIG).

**Strength & Quality of Evidence**
- Weak
- Very Low-Quality Evidence

**Recommendation #46**

In critically ill adults with COVID-19, we **suggest against** the routine use of convalescent plasma.

**Strength & Quality of Evidence**
- Weak
- Very Low-Quality Evidence

**Recommendation #47.1**

In critically ill adults with COVID-19 we **suggest against** the routine use of lopinavir/ritonavir.

**Strength & Quality of Evidence**
- Weak
- Low-Quality of Evidence

**Recommendation #47.2**

There is **insufficient evidence** to issue a recommendation on the use of other antiviral agents in critically ill adults with COVID-19.

**Recommendation #15**

There is **insufficient evidence** to issue a recommendation on the use of recombinant rIFNs, alone or in combination with antivirals, in critically ill adults with COVID-19.

**Recommendation #48**

There is **insufficient evidence** to issue a recommendation on the use of chloroquine or hydroxychloroquine in critically ill adults with COVID-19.

**Recommendation #49**

There is **insufficient evidence** to issue a recommendation on the use of tocilizumab in critically ill adults with COVID-19.

**Recommendation #50**

There is insufficient evidence to issue a recommendation on the use of tocilizumab in critically ill adults with COVID-19.

**Recommendation #48**

There is **insufficient evidence** to issue a recommendation on the use of recombinant rIFNs, alone or in combination with antivirals, in critically ill adults with COVID-19.

**Recommendation #49**

There is **insufficient evidence** to issue a recommendation on the use of chloroquine or hydroxychloroquine in critically ill adults with COVID-19.

**Recommendation #50**

There is insufficient evidence to issue a recommendation on the use of tocilizumab in critically ill adults with COVID-19.